Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

k related to the PROCAPS agreement which we terminated in 2012 and decreased litigation costs related to a settlement in 2011.

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.

Forward Looking StatementsThis press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others.  They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product c
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today ... will host a,conference call and webcast on Tuesday, ... discuss first quarter 2008 financial results., ... International Dial-in Number: 617.597.5308 Participant Code: ...
... Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in the ... of the newly created Next Biotech Index of,NYSE Euronext. ... company,for this index," said Ronald Lorijn, CEO of AMT. ... and will help investors to track,the performance of our ...
... and Patient Report,Transfer Across Disparate PACS and Maintains Hospital Group,s ... ... RIS Crashes, SEATTLE, April 8, 2008 Compressus, ... of an integrated digital imaging and data management,solution at E-Rad ...
Cached Biology Technology:BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET) 2Amsterdam Molecular Therapeutics Part of Next Biotech Index 2Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers 2Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers 3
(Date:4/17/2014)... our ideas about domestication derive from Charles Darwin, ... British animal-breeding practices during the 19th century, a ... , It is from Darwin that we ... captive animals from wild species and total human ... animal management in this industrial setting has been ...
(Date:4/16/2014)... University researchers have identified a new syndrome called "osteosarcopenic ... muscle mass with obesity. , "It used to be ... your bones would be because the bones were supporting ... of Nutrition at Florida State. "But, that,s only true ...
(Date:4/16/2014)... Professor Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has just ... (NIH) in the amount of nearly US$600,000. The 5-year grant ... proteins called RNases and to explore their biomedical potential in ... asthma. , "Receiving a grant at this level ...
Breaking Biology News(10 mins):The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... have so far been starch and cane sugar. In ... University study was to use only lignocellulose, otherwise known ... production. Another new breakthrough in the ... biotechnology. Finland,s advanced forest industry provides particularly good opportunities ...
... In an example of life imitating art, biologists ... living neon sign composed of millions of bacterial cells ... Their achievement, detailed in this week,s advance online issue ... fluorescent protein to the biological clocks of the bacteria, ...
... that could revolutionize biomedical research, scientists have discovered a way ... from an individual cancer patient alive in the laboratory ... in the lab after dividing only a few times, and ... body. This new technique, described today online in the ...
Cached Biology News:Chemicals and biofuel from wood biomass 2Researchers create living 'neon signs' composed of millions of glowing bacteria 2Researchers create living 'neon signs' composed of millions of glowing bacteria 3Georgetown researchers lead discovery expected to significantly change biomedical research 2
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Biology Products: